This paper presents a comprehensive overview of the pharmacokinetic parameters used from in vivo and in vitro studies that are important in order to understand the major conceptual approaches of toxicokinetics and the disposition of environmental chemicals. In vitro biochemical information concerning the detoxication of environmental chemicals is also presented. showing the usefulness of the pharmacokinetic equations and providing confidence in using the approach for in vitro-in vivo correlations. Ultimately, the presentation may provide the reader with a conceptual framework for future evaluation of the human health risks associated with environmental toxicants. Environ Health Perspect 1 04(Suppl 1 ): 23-40 (1996) 
Introduction
For over 25 years, the concept of bioactivation of chemicals to reactive intermediates that covalently modify critical proteins and DNA, which in turn alter key cellular function, ha; been thoroughly established. Examples of the bioactivation of chemicals to form toxic substances following the paradigm developed many years ago ( Figure 1 ) and refined in terms of mechanism and site of action have been reported for numerous chemicals including bromobenzene, acetaminophen, aflatoxin, polycyclic aromatic hydrocarbons, arylamines, and organophosphates to name a few (1) . The purpose of this review is to present an overview as to how in vitro and in vivo pharmacokinetic parameters could be useful in understanding the conceptual framework for the disposition and detoxication of environmental chemicals.
While the ability to predict which chemicals will follow the events oudined in Figure 1 is instrumental to the prediction of to;-;icity of a chemical, the prediction of metabolic detoxication could be equally important. In general, the details of metabolic detoxication are less appreciated than the science of metabolic bioactivation of chemicals to toxic species. This perspective will focus on the molecular basis for chemical detoxication. Where possible, the significance of metabolic detoxication to environmental chemicals will be presented. The detoxication enzymes that will be discussed in detail include cytochromes P450, flavin-containing monooxygenase (FMO), carboxylesterases and other esterases, as well as glucuronosyltransferases. As a prelude to the presentation of examples of metabolic detoxication of environmentally relevant chemicals, we wi!l first describe some general approac'hes to examine the role of in vitro metabolism studies in the prediction of in vivo toxicity data.
The manifestation of clinical toxicity of chemicals is often dependent upon the peak plasma concentration achieved, the duration of exposure to the toxic entity above a particular threshold, or the amount of toxin accumulated in the body. To determine the exposure to the toxic entity and to assess the impact of such exposure, one needs to answer the following questions: How much of a chemical gets into the systemic circulation and to the site or organ of bioactivation? Where in the body will the chemical distribute? How The basic principle of toxicokinetics used in environmental science is directly derived from pharmacokinetics. Toxicokinetic parameters of a specific chemical in man can be predicted by allometrically scaling the corresponding parameters obtained in animals. These phamacokinetic/toxicokinetic parameters in animals can be obtained from in vivo studies. The parameter clearance, can be estimated from in vitro metabolism data also. Derivation of parameters used in pharmacokinetics can be found in reviews and textbooks (2-4) and will not be described in detail here. An overview of several equations useful for calculating fundamental pharmacokinetic parameters from in vivo and in vitro data will be presented, and parameter scaling by allometry will also be introduced and contrasted to physiological modeling.
Quatttng Expour
From in vivo studies in which the chemical of interest is given to animals, blood or plasma concentrations of a chemical at various time points are usually available and determined. When steady state is reached after multiple dosing or with constant infusion, the concentration (Ca,) can be predicted as C55=Fxdose/(txCL) [1] where t is the dosing period, CL is the total clearance, and Fis the bioavailability.
The term clearance describes the rate at which a chemical is eliminated from the body. Clearance may be calculated as the available dose (Fx dose) divided by the area under the systemic chemical concentration-time profile (AUC):
CL= Fx dose /AUC. [2] Substituting Equation 2 into Equation 1, one will obtain C55=AUC/t. [3] Thus, the ability to correctly predict Ci, is dependent upon the accuracy of the measurement ofAUC. The bioavailability (F) of a chemical product via various routes of administration/exposure is defined as the fraction of unchanged chemical that is absorbed intact and reaches the systemic circulation following administration by any route. For an intravenous (iv) dose of a compound, bioavailability is defined as unity. For chemicals administered by other routes of administration, bioavailability is often less than unity:
F=AUCnon iv/AUCiv [4] In many instances, the response to a particular chemical exposure, particularly toxicity, is related to the amount of a chemical in the body rather than to the systemic concentration. The amount in the body at steady state (Ass) is the product of the systemic concentration and the steadystate apparent volume of distribution (Vss):
A,,= CG5x Vs. [5] The apparent volume of distribution relates the amount of chemical in the body to the concentration of the chemical in the blood or plasma. The apparent volume of distribution does not represent a real volume. Rather, it is an apparent volume that should be considered as the size of the pool of body fluids that would be required if the chemical was equally distributed throughout all portions of the body. At steady state, V., reflects the sum of the volumes of all the pools into which the chemical may distribute. V,, can be calculated from the AUMC, area under the moment curve (i.e., an integration of the concentration x time vs time profile), and AUC as defined by Benet and Galeazzi (5):
VI =dosejvxAUMC/AUC2. [6] Half-life (t1/2) is also an extremely useful kinetic parameter for assessing exposure to a chemical. By definition, half-life is the time required for 50% of the chemical remaining in the body to be eliminated. It is the relationship between the apparent volume of distribution and the total clearance: tl/2=0.693x V/CL. [7] If the dosing interval (proportional to 1/exposure frequency) is short relative to half-life, significant accumulation will occur. Thus, the half-life parameter allows one to predict chemical accumulation within the body and quantitates the approach to plateau that occurs with periodic or constant toxicological/environmental insult.
Toxins with very short half-lives may have a smaller impact on human health because they will have a problem maintaining concentration levels at which toxicities may occur. On the other hand, chemicals with very long half-lives will accumulate in the body and possess negative characteristics in terms of toxicities. However, if toxicity occurs as a result of the formation of toxic metabolites, then it is the half-lives of such toxic metabolites that will form a relationship with the level of toxicity exposure.
Among the parameters mentioned above, clearance can sometimes be found from in vitro studies. For [8] The intrinsic ability of an organ to metabolize a chemical is directly proportional to the activity of the metabolic enzymes in the organ. Such metabolic processes are characterized by MichaelisMenten kinetics:
Rate of metabolism= Vm,, X C/(Km + C) [9] Environmental Health Perspectives * Vol 104, Supplement * March 1996 in which Vmax, the maximum rate at which metabolism can proceed, is proportional to the total concentration of enzyme. Km is the Michaelis-Menten constant corresponding to the chemical concentration that yields 1/2 of the maximum rate of metabolism. Dividing both sides of Equation 9 by the substrate concentration in the organ (assuming the same free concentration at the metabolic site in vitro and in vivo and in the venous blood) yields:
Rate of metabolism/C= Vmax/(Km + C) = CLhep/fu. [10] Since identification of saturable metabolism only occurs for low extraction ratio compounds (3) The allometric approach will be described in detail, and the physiological modeling approach will be briefly discussed.
Aliometric Saling
Interspecies scaling is a method of interpolation and extrapolation of the underlying anatomical, physiological, and biochemical similarities in mammals. Many of these similarities, or differences, are related to the size of the species. It has been recognized that many of the physiological parameters (7) that ultimately determine the values of various pharmacokinetic parameters are related across species according to their body weights raised to a certain power (7) . This relationship between the rate of biological processes and body weights is linked by the metabolically active mass in a unit termed the ergosome (8) . The metabolically active mass is hypothesized to correlate with the rate at which oxygen and oxidizable materials are delivered to metabolically active cells (8) . The size of the metabolically active mass, or the number of ergosomes a species has, equals B', where B, is the body weight, and n is the allometric exponent (8) . Thus, the rationale for normalizing data on the ordinate by a power function of body weight is based upon this premise. Allometric equations that relate a physiological variable to a oneterm power function used in concert with the body weight are generally represented as Y=aBn. [13] It has also been found that, at times, the single-term power function is incapable of fully characterizing biological and pharmacokinetic processes for all mammals. Sacher (9) found that by accounting for [14] processes such as the maximum lifespan potential can be more adequately described (9) . Pharmacokinetic processes such as intrinsic clearance for compounds eliminated by the mixed function oxidases (10), when expressed relative to maximum lifespan potential instead of chronological time, also c6rrelate well with body weight across species (11) (12) (13) . Because the allometric exponents for most biological processes, with some exceptions, are less than 1 (7), it is apparent that smaller animals will have smaller individual physiological variables than the larger animals. Yet, it was discovered that, for all species, a constant relationship exists between particular physiological variables within each species. For example, the breath:heartbeat ratio is 4 for all mammals regardless of their sizes (14) , or the number of heartbeats per maximum life span is 8.6x 108 (15 (14) . Each species is endowed with its own particular ideal (mathematical) space-time continuum, which in turn is related to the organism's total body mass (8) . A summary of the different pharmacokinetic-space-time parameters is presented in Table 2 (8, 16) . [16] then plasma concentration (C) after an iv bolus dose is as follows, assuming Z equals 0: C=(DIV)e-kt [17] [18] C/(D/B7) = (/b)e-(a/b)(t/BY-x) [19] Hence, the parameter on the ordinate will be normalized by dose per body weight raised to the power of y, and the time on the abscissa will be normalized by By (Figure 2 ) with the complex Dedrick plot (8) . The beauty of using allometric scaling is that pharmacokinetic parameters can be easily related from one species to another by a simple expression (8) . For example: t1/2 man=t,/2 dog (Bman/Bdog)YX [20] Recent work by Lave et al. (20) reported that increased accuracy in the prediction of clearance of mafarotene, a compound eliminated exclusively by metabolism, can be achieved by integrating in vitro metabolic data with in vivo pharmacokinetic data from animals. In vivo clearance from each animal species is normalized by the ratio of in vitro metabolic clearances in the corresponding animal species and man ( Figure 3 ):
CLrat, normalized= CLrat X CLman, microsomes /CLrat, microsomes [21] The in vitro metabolic clearances can be obtained from either hepatocyte or microsomal incubation data, as described by Equation 10 . The normalized clearance values in animals were then extrapolated to humans using allometric scaling (Figure 3 ).
Allometric scaling is useful not only in estimating individual pharmacokinetic parameters (21) (22) (23) (24) but also in estimating the entire pharmacokinetic profile (25) , as well as toxicity end points (15) . It may also offer a way to determine which larger animal to use in toxicology testing (15) and what doses to use in toxicity testing (15) ; allometric scaling potentially leads to the reduction of the numbers of subjects needed in a study (26) .
Physiological Modeling
A physiological model is composed of a series of lumped components (body regions) representing organs or tissues in physiologic model is shown in Figure 4 . (27) and toxicity in different species (28) , once the model is described in detail in one species. It also allows extrapolation from high dose to low dose and vice versa. As compared to the allometric approach, it has the advantages of being capable of describing situations in which nonlinearities occur, showing the differences from various routes and frequency of administration, or making a priori predictions of pharmacokinetic changes associated with various disease states, age, pregnancy (29) , or drug-drug interactions. In addition, physiologically based pharmacokinetic modeling can also be used to model surrogates in tissue compartments (15) .
As described above, once pharmacokinetic parameters are obtained via either in vitro methods or in vivo animal studies, the next task is to extrapolate the information to humans. Below, we provide an example of an in vitro-in vivo correlation of an environmental chemical, (S)-nicotine, to which humans are widely exposed.
In VtoIn Vivo Metabolic Correiations of(S)-Nicotine
In the United States, approximately 75 million people smoke tobacco (30) . Approximately 400,000 deaths occur every year in the United States from tobacco smoking, primarily from lung cancer and respiratory and heart disease (31). Recently, it has been concluded that approximately 3,000 lung cancer deaths occur in the United States annually from environmental tobacco smoke in nonsmokers (32) . Passive smoking may also be responsible for some 150,000 to 300,000 cases annually of bronchitis and pneumonia in U.S. children (31) . There are a large number of constituents in mainstream and sidestream smoke from cigarrettes that could contribute to the untoward health effects described for smoking tobacco. (S)-Nicotine is one of the major components of tobacco and formation of (S)-cotinine and (S)-nicotine N-1'-oxide in humans are useful markers of (S)-nicotine exposure because both metabolites are chemically stable and because the metabolites are formed by different enzyme systems (33) .
In vitro kinetic studies showed that in the presence of adult human liver microsomes, the mean Km apparent value for formation of the iminium ion (that is subsequently converted to (S)-cotinine by the action of exogenously added aldehyde oxidase) was 39.6 pM (range 3-75 pM) (34) .
Interestingly, of the 13 microsome samples from which the data were obtained, three samples gave mean Km apparent values of 482 pM, over 10-fold greater than the normal mean values. The Km apparent value for FMO3-mediated (S)-nicotine N-1'-oxide formation in the presence of human liver microsomes is probably greater that 800 pM, almost 20-fold more than that for cytochrome P4502A6 formation of (S)-nicotine Al'5'-iminium ion.
Thus, the relatively low percent of (S)-nicotine N-i'-oxide that is formed in vivo compared with (S)-cotinine probably reflects the fundamental kinetic properties of adult human FMO3 versus cytochrome P4502A6. In vitro data suggest that approximately 90% of the formation of (S)-nicotine A1'5'-iminium ion could be explained by the action of cytochrome P4502A6. However, there may be a cytochrome P4502A6 polymorphism or differential expression in human liver preparations, and it is possible that the intersubject variability in human liver microsome samples for (S)-nicotine Catom oxidation observed may underlie the large interindividual variability observed for (S)-nicotine metabolism in vivo. Thus, use of in vitro metabolic correlations has identified the type of cytochrome P450 responsible for iminium ion formation (i.e., CYP2A6); it has provided considerable insight into the relative amount of adult human FMO3 versus cytochrome P4502A6-mediated (S)-nicotine metabolism; and finally, it has provided understanding about the fundamental molecular basis for interindividual differences in (S)-nicotine metabolism in humans ( Figure 5 ).
Although considerable interindividual variability in both the amount of (S)-nicotine present and the type of metabolite formed [i.e., (S)-cotinine or (S)-nicotine N-1'-oxide] was observed in humans following intravenous, dermal, or free-smoking routes of administration, nevertheless, quantification of each metabolite provided information about two potentially disparate metabolic pathways [i.e., flavincontaining monooxygenase-catalyzed formation of (S)-nicotine N-1'-oxide and cytochrome P450-catalyzed (S)-nicotine A"5'-iminium ion] (33). The metabolic formation of the N-1'-oxide probably represents a detoxication pathway for (S)-nicotine, whereby the polar, highly ionized N-1'-oxide is readily excreted in the urine. On the other hand, formation of (S)-nicotine Al"5-iminium ion potentially represents a bioactivation mechanism because the iminium ion has been shown to covalently modify tissue macromolecules.
The pharmacological activity of As described above, (S)-nicotine undergoes extensive Phase I oxidative metabolism in humans, and approximately 90% of a dose can be accounted for in terms of urinary metabolites. In the presence of adult human liver microsomes, cytochrome P4502A6 appears to be the major enzyme that forms (S)-nicotine A1"5'-iminium ion that is converted to (S)-cotinine by aldehyde oxidase (36) . Because it appears that cytochrome P4502A6 and aldehyde oxidase work in concert to produce a detoxicated end product of (S)-nicotine, it is possible that humans with a deficiency of aldehyde oxidase are predisposed to an increased risk of the untoward effects of (S)-nicotine At"5'-iminium ion. In addition, polymorphism leading to a reduction in the ability of a subpopulation of humans to metabolize (S)-nicotine by cytochrome P4502A6 could also result in longer halflives of (S)-nicotine and result in increased pharmacological and behavioral effects.
While the pharmacological and neurochemical effects of increased accumulation of (S)-nicotine A1'5'-iminium ion in humans who are unable to oxidize the iminium ion are unknown, they are likely to be considerably more toxic than exposure to increased levels of the rapidly excreted (S)-nicotine N-i'-oxide.
Of the two (S)-nicotine N-1'-oxide diastereomers that could be formed in humans, the absolute stereoselective formation of only the trans diastereomer has been used as a selective functional probe of adult human FMO activity (33, 36) . Administration of a mixture of (S)-nicotine N-i'-oxide diastereomers by either free-smoking, intravenous, or dermal routes to humans showed that the N-1'-oxide was not appreciably N-1'-oxidized or reduced (33) . If efficient reduction of metabolically formed (S)-nicotine N-1'-oxide to (S)-nicotine in humans occurred, it could explain the relatively low amount of N-i'-oxide formed in vivo. That (S)-nicotine N-1'-oxide reduction is not observed in vivo (33) suggests that metabolic futile cycling between nicotine N-1'-oxide and tertiary amine does not provide a reservoir for the pharmacological action of (S)-nicotine. Thus, previous reports in animals describing the reduction of (S)-nicotine N-1'-oxide to the tertiary amine is probably due to gut bacteria metabolism via the oral route of administration (37 
Flavin-containing Monooxygenase
The action of FMO constitutes an important means of terminating the pharmacological and toxicological action of a wide number of xenobiotics including (S)-nicotine. As seen for numerous other tertiary amines, FMO-catalyzed N-oxygenation converts a biologically active compound into a polar, readily excreted tertiary amine N-oxide. FMO also catalyzes the oxygenation of organosulfur-, selenium-, phosphorous-and other heteroatom-containing chemicals that are likewise more efficiently excreted after oxygenation. In contrast to cytochromes P450, FMO generally converts heteroatom-containing compounds to products with decreased potential for toxic or carcinogenic properties. Cytochromes P450 can oxidize nucleophilic heteroatoms to heteroatom oxides that in some cases are the same as the products from FMO, but cytochrome P450 does so considerably less efficiently than FMO. Another fundamental difference between cytochrome P450 and FMO is the apparent one-versus twoelectron enzyme mechanism of oxidation of each monooxygenase, respectively. Consequently, cytochrome P450-mediated oxidation has been implicated in numerous co-oxidative and free radical processes, many of which are destructive to cellular macromolecules and tissue. The two-electron oxygenation mechanism of FMO does not preclude the enzyme from participating in metabolizing some chemicals to toxic metabolites (38) . One notable example is the conversion of secondary arylamines to the corresponding aryl hydroxylamine. Another example comes from the N-oxygenation of a tertiary amine to an unstable tertiary amine N-oxide that undergoes Cope-type elimination to produce a hydroxylamine and an olefin (38) . It is possible that the hydroxylamine formed could possess untoward pharmacological properties. In principle, FMO-mediated aryl hydroxylamine formation and subsequent esterification or sulfation may contribute to the carcinogenic properties of arylamines (39) . However, the contribution of this particular aspect of arylamine metabolism has not been fully addressed because many of the animal models used in carcinogenicity testing do not possess high levels of the hepatic form of FMO present in adult humans. For example, although it is recognized that there are five distinct FMO gene subfamilies encoding five forms of mammalian FMO, the most functionally prominent form of the enzyme in adult human liver (i.e., FMO3) apparently is not present to a great extent in adult rat liver, a commonly used animal for drug and chemical metabolism and toxicity studies (38) . Less is known about the factors that control FMO regulation; hormone and dietary factors appear to regulate FMO expression, but this is species and tissue specific and probably occurs independently of other factors.
As discussed above, it is likely that the major form of FMO in adult human liver is distinct from that present in many experimental animals. Regardless, it has been observed that in species which are deficient in FMO, shunting of the metabolism of a toxin to the cytochrome P450 pathway occurs and makes the animal quite susceptible to the toxic properties of the chemical. On specific role in detoxication has begun to be examined. Notwithstanding the recent advances in the study of the recombinant human enzyme, the current understanding of the role of carboxylesterase in the detoxication of chemicals has largely been extrapolated from in vitro and in vivo studies in the rat. One caveat to correlations of this type is the fact that rats have higher endogenous levels of carboxylesterases than primates, and this difference could account for the lower sensitivity of rats to xenobiotics that are more toxic as the ester than as the hydrolysis product (41) . Where possible, this review will examine the specific role of human esterase D (EsD) in the detoxication of xenobiotics. However, some information from rats (or other animals) will be presented because this information is relevant to the possible role of EsD in the detoxication of chemicals in humans.
Carboxylesterases catalyze the hydrolysis of ester, thioester, and sometimes amide bonds during the course of metabolism of xenobiotics and endogenous chemicals (Figure 6 (Figure 7) (42-44) . Although malathion-type carboxyl ester hydrolysis and detoxication primarily occur in the liver and plasma, it has been shown that human carboxylesterase found in the skin also functions to detoxicate organophosphates (45) . However, when malathion-type compounds are subject to metabolic activation to the corresponding oxon, the hydrolysis of the carboxylic acid does not occur-rather inhibition of the carboxylesterase by the phosphonothiolate moeity is the preferred fate (Figure 8 ) (46) . For the oxon metabolite, detoxication is the result of stoichiometric sequestering by the enzyme rather than a result of 0 II R-C-X-R catalytic hydrolysis by carboxylesterase. A similar metabolic fate has been shown for simple phosphorothionates (e.g., chlorpyrifos, Figure 9 ) when biotransformed to the oxon in mouse or rat (47) (48) (49) (50) organophosphorus nerve agents developed for chemical warfare. This is of particular importance because of the recent terrorist poisoning in Japan using sarin. It has been shown in rats that irreversible binding of soman to liver and plasma carboxylesterase accounts for a significant portion of its rapid detoxication of the soman P(-) isomers. In contrast, the P(+) isomers are largely detoxicated by A-esterases ( Figure  10) 
Detoxication ofChemicals ofEnvironmental Concern
Carboxylesterase has also been shown to have a role in the detoxication of various environmental chemicals. Some representative compounds are shown in Table 3 . The mode of carboxylesterase-mediated detoxication of the compounds listed in Table 3 is hydrolytic cleavage of a carboxylic acid ester moiety to give the corresponding carboxylic acid and alcohol (Figure 11 ). Other metabolic processes can and do occur for the compounds listed in Table 3 , but hydrolysis by carboxylesterase is generally looked upon as a means of producing more polar materials with considerably less toxic potential.
Hydrolysis of Drug
Carboxylesterases in the liver, gut, and other tissues have been shown to be important in the hydrolytic detoxication of certain drugs (67) . Representative examples of drugs of this class that are substrates for carboxylesterases are listed in Table 4 . In addition, carboxylesterases have been shown to be efficient hydrolytic catalysts for a number of physiologically important compounds including steroid and lipid esters. Recently, the characterization of a human liver carboxylesterase that hydrolyzes and transesterifies (-)-cocaine has been reported (73) . The product of (-)-cocaine hydrolysis by this esterase is benzoylecgonine, a metabolite that is largely inactive as a pyschomotor stimulant (Figure 12 ). The Km value for formation of benzoylecgonine (i.e., 116 WM) is much greater than the concentration of (-)-cocaine reported to be in the blood following a 100 mg intravenous dose of (-)-cocaine (i.e., 3 Figure 11 . Some examples of environmentally important esters that are hydrolyzed by carboxylesterase. (-)-cocaine overdose is reported to be in the range of 30 to 460 mg/lOOml, it is possible that transesterification of (-)-cocaine with ethanol constitutes a metabolic pathway contributing to increased toxicity of (-)-cocaine (73) . Thus, in addition to the well-recognized serum cholinesterase or butyrylcholinesterase that catalyzes the hydrolysis of (-)-cocaine to ecgonine methylestester, a new human liver carboxylesterase has been discovered that hydrolyzes the methyl ester of (-)-cocaine to a pharmacologically inactive metabolite (i.e., benzoylecgonine) and a pharmacologically active transesterification product, (-)-cocaethylene ( Figure 12 ) (73) . Possibly the balance between (-)-cocaine ester hydrolysis and transesterification for any particular human subject may contribute to the overall susceptibility of the individual to the toxic properties of (-)-cocaine. (74, 75) . The natural substrate for this enzyme has recently been identified as 0-acetylated sialic acid, and one suggested endogenous role of EsD has been hypothesized to involve the reuse of sialic acids (76) .
Purification of EsD has been accomplished from human erythrocytes (77) (78) (79) , and the biochemical properties of the purified enzyme have been reported. EsD is an enzyme with a molecular weight of 34 kDa as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis; the Km of EsD for the substrate 4-methylumbelliferyl was determined to be 10 pM.
It is interesting to note that mercuric chloride and p-chloromercuribenzoate both inhibited the purified enzyme completely at low concentrations (1.0 mM), which suggests that an SH group is necessary for the enzymatic reaction (77) . In addition, purification of EsD allowed the preparation of polyclonal and monoclonal antibodies from rabbit and mouse, respectively, that have been useful for immunoquantification studies.
The EsD gene (from human erythrocytes and human liver) has now been cloned and sequenced (78, (80) (81) (82) (83) and has been localized to chromosome 13 band q14 (78, (80) (81) (82) (83) (84) (85) (86) (87) . EsD has been shown to exhibit strong homology to two other esterases [i.e., acetylcholinesterase (AChE) from Torpedo californica and esterase-6 of Drosophila] (81) . Homologous regions were detected about the consensus sequence serine-containing active site region. From studies of sequence homology, the active site is believed to contain the peptide isoleucine-phenylalanineglycine-histidine-serine-methionineglycine-glycine. The residues thought to participate in catalysis are serine, histidine, and aspartic acid (82) . The human liver carboxylesterase gene has also been recently cloned and characterized (83,87j88) ; it showed significant sequence homology to various mammalian carboxylesterases. Furthermore, sequence analysis of human liver carboxylesterase and the genes for human cholinesterase and cholesterol esterase suggests an evolution from a common ancestral gene (88) .
Although EsD was known to be present in a variety of tissues, quantification has only recently been accomplished by using the specific substrate 4-methylumbelliferyl acetate (77) . The results from this study showed that most EsD activity was found in the liver. Significant activity, although less than that of the liver, was also identified in the human kidney. Although little EsD enzyme activity was observed in the lung, recently a carboxylesterase from the lung (i.e., alveolar macrophage) has been purified and appears to be identical to EsD (89) . The results suggest that EsD in the lung may play a role in the detoxication of inhaled xenobiotics. Carboxylesterase has also been identified in human blood monocytes (52, 90) . Another site that has been observed to contain carboxylesterase activity is the human skin (45) , which suggests that EsD may play a role in the detoxication of absorbed xenobiotics.
Carboxylesterase activity has also been identified in human nasal tissue, suggesting a role of this tissue in the detoxication of inhaled xenobiotics as well (91) . However, hydrolysis of certain inhaled esters has been correlated to lesions of the olfactory epithelium in rats due to transformation of inhaled chemicals into toxic substances rather than detoxicated metabolites (90, 92) . The data suggest that hydrolytic metabolism of inhaled esters in this tissue may play a significant role in the bioactivation of such substances rather than degradation and detoxication. It is possible that accumulation of some of the metabolites of inhaled esters contributes to the pathogenesis of ester-induced nasal lesions. In like fashion, it has been suggested that carboxylesterase-mediated hydrolysis of vinyl acetate generates acetaldehyde, an intracellular cross-linking agent possibly contributing to tumorigenesis (93) .
The hydrolysis of lipophilic esters is a major route for the detoxication of environmental chemicals such as pesticides. Human exposure, either from occupational or passive administration, may occur via absorption by the skin or the respiratory tract. Therefore, carboxylesterase-mediated hydrolysis of xenobiotics in these tissues, as well as in the liver, may contribute to influencing the toxicity of potentially toxic esters.
Paraoxonase/Arylesterase (A-estrase)
It is worthy to briefly discuss the enzyme paraoxonase/arylesterase in light of the previous presentation of the metabolism of organophosphorus compounds. Paraoxonase/arylesterase has been shown to hydrolyze and therefore detoxicate many phosphate esters or phosphorothionates (i.e., organophosphorus insecticides) that have undergone metabolic activation to the oxon structure (Figure 8 ) before these compounds reach the target tissues containing acetylcholinesterases. Two paraoxonase/arylesterases that possess the ability to hydrolyze paraoxon and a variety of organophosphorus compounds, as well as arylesters, have been identified in human serum (94) (95) (96) . One was shown to be an ethylenediaminetetraacetic acid (EDTA)-sensitive esterase while the other was identified as an EDTA-insensitive paraoxonase. The highest levels of activity have been found in liver and serum. Like many other esterases, no known endogenous substrates for paraoxonase/arylesterase have been identified. It has been shown that calcium is required for paraoxonase/arylesterase, but the mechanism for the interaction with calcium is unknown at this time (97, 98) . Recently it has been shown that the enzyme is not a cysteine esterase as commonly thought for many years; the mechanism of mammalian paraoxonase/ arylesterase must be reconsidered in light of this new finding (99 group to a large number of endogenous compounds and xenobiotics ( Figure 13) . Figure 14 . Hypothetical scheme depicting the metabolic bioactivation and glucuronidation of a procarcinogen, which is transported to another cell that possesses low bioactivation capacity and, nevertheless, accumulates sufficient metabolite to show significant toxicity. (112) . These compounds may account, at least in part, for the positive correlation between cigarette smoking and the incidence of bladder cancer in humans (113 (115, 116) . However, it is possible that the same transport form may also contribute to delivering the aromatic amine to an extrahepatic site and increasing the toxic potential of the amine at that site. Another example of an environmental chemical, 2-hydroxybiphenyl, is widely used as an antimicrobial agent to protect edible crops, and it is possible that the human population may be exposed to it. However, it is likely that human exposure to 2-hydroxybiphenyl does not pose a significant health hazard because, at low doses, 2-hydroxybiphenyl is efficiently excreted as a glucuronide and as a sulfate ester; no significant toxicity has been observed (104, 117) .
Mechanism of Glucuronosyltransferases
Uridine-5'-diphospho-a-D-glucuronic acid (UDPGA, Figure 13 ) is the donating coenzyme during the glucuronidation reaction.
The UDPGTs are a group of closely related membrane-bound enzymes that are responsible for the transfer of the glucuronosyl group from UDPGA to many endogenous and exogenous chemicals having nucleophilic functional groups (i.e., X in Figure 13 ). The mechanism of the glucuronidation catalyzed by UDPGTs is envisaged to take place via an SN2 reaction-the nucleophilic group of the substrates attack the C1 of the pyranose acid ring of UDPGA-which results in the formation of the glucuronide ( Figure 13 ). As shown in Figure 13 , the attacking groups of the substrates should have sufficient nucleophilic character for a high rate of glucuronidation. There is a wide variety of groups that fulfill this requirement, e.g., phenols (phenol, morphine), carboxylic acids (bilirubin, valproic acid), alcohols (t-butanol, many steroids), and hydroxamic acids (N-hydroxy-2-acetylaminofluorene) to form O-glucuronides; thiophenols (thiophenol), and carbamic acids (diethyldithiocarbamic acid) to form S-glucuronides; and aromatic amines (aniline), hydroxylamines (N-hydroxy-2-naphthylamine), and tertiary amines (cyproheptadine) to form N-glucuronides (Table 6 ). Even carbon atoms can attack the C1 atom of the glucuronic acid ring if the carbon atom is sufficiently nucleophilic (sulfinpyrazone, phenylbutazone) to form Cglucuronides (1 18) ( Table 6 ). The reactivity toward forming a glucuronide will depend on the chemical structure, including both electronic and steric factors. A second requirement for a high rate of enzymatic glucuronidation is for sufficient lipid solubility of the substrate.
The resulting glucuronide is usually devoid of any significant biological and pharmacological activities. A family of homologous UDPGT isoenzymes is located in the endoplasmic reticulum of the liver, as well as in other tissues (119) . Purification of the transferases catalyzing glucuronidation proved difficult because the enzyme was found to be anchored in the membrane of the endoplasmic reticulum (120) ; however, the difficulties involved in of the individual isoenzymes and as a system for study of substrate transport, glucuronidation, and export of glucuronides in whole cells in vitro (91) . The study of UDPGTs in humans has also shown that several diseases are directly related to these enzymes. Crigler-Najjar syndrome is a familial form of severe unconjugated hyperbilirubinemia caused by a dysfunction in bilirubin glucuronidation in humans (125) (126) (127) . Gilbert syndrome is a benign, mild, unconjugated hyperbilirubinemia that is found in approximately 5% of the population (128) (129) (130) .
As described previously, although it seems that most xenobiotic glucuronides are detoxicated via the action of UDPGTs, glucuronidation may also lead to toxic effects in certain cases, especially at high dose levels. A well-studied example is choleresis by glucuronides. In general, glucuronide excretion in bile causes choleresis of approximately 15 to 20 pil bile jimol-' glucuronide (131) . However, the phenolic drug hormol causes cholestasis at a high dose in the rat because harmol glucuronide is excreted to such a high extent in bile that the glucuronide precipitates and the bile channel becomes blocked (132) . As discussed above, glucuronosyl conjugates can reenter the liver and hydrolyze back to the original substrate as shown in Figure 15 in an apparent metabolic cycling process.
There is no doubt that this is also a factor in any glucuronide-mediated toxicity.
It is possible that glucuronosyl conjugates can become chemically reactive intermediates and participate in further metabolism, such as acyl glucuronide formation ( Figure 15 ). For example, tolmetin, the nonsteroidal anti-inflammatory drug used for the treatment of rheumatoid arthritis may be converted to a reactive acyl glucuronide that contributes to adverse side effects observed in humans. In humans, tolmetin is primarily metabolized by oxidation on the methyl group of the phenyl ring and by conjugation of the carboxylic acid to produce the O-acyl glucuronide. The O-acyl glucuronide may hydrolyze, participate in acyl migration reactions, or covalently bind to human serum albumin. It is the irreversible binding of tolmetin glucuronides to human serum albumin that is thought to be responsible for the allergenic properties of tolmetin. It is possible that other nonsteroidal anti-inflammatory agents also possess this unfavorable property. In addition, it is likely that other carboxylic acids that participate in acyl glucuronidation may likewise produce metabolic intermediates that covalently modify important cellular proteins and produce untoward effects.
Regulation of Glucuronosyltransf;erases
Most investigations of the regulation of glucuronosyl transferases have been conducted in animals, even though some in vivo and in vitro studies have been done in humans (133, 134) . Study of the regulation of UDPGT levels related to different diets has been conducted in the rat. The results suggest that an iron-deficient diet can cause depression in UDPGT enzyme activity (135) . Rats fed a diet rich in turmeric can significantly elevate UDPGT activity (136) but a vitamin E-deficient diet had no effect on the activities of UDPGT (137) . Most experimental data about UDPGTs have been obtained from rats, chickens (138) , rabbits (139) , and monkeys (129) in vivo and in vitro, but the data and theory may be able to be applied to humans.
The importance of Phase II reactions by UDPGTs in humans and other animals has also been investigated (139, 140) . However, in vivo studies of humans are limited, even though there are some research groups that have investigated the formation of glucuronides in humans through the analysis of urine and bile (141, 142) . Pharmacokinetic modeling of drug conjugates in vitro has been well established such that steady-state rate equations for the simulation of conjugation and deconjugation reactions have been developed (107) . Simulations with massbalance equations have proven useful in the understanding of conjugation and deconjugation processes in vivo (143) . Through these efforts, a more quantitative interpretation of metabolic data on conjugation reactions has been obtained.
Concluding Remarks
An examination of the pharmacokinetic parameters that contribute to some of the major conceptual approaches to understanding toxicokinetics and the disposition of environmental chemicals has been presented. By the use of in vitro measurements and in vivo correlations, it is possible to predict with a good deal of certainty the extent of metabolic clearance and other important kinetic parameters. Determination of clearance invariably leads to a clearer understanding of the contribution, if any, to the toxicity of a drug or the residence time of a potentially toxic metabolite. The concept of interspecies scaling in the interpolation and extrapolation of fundamental biochemical metabolic processes has been presented. In the future, we anticipate that physiological modeling and allometric scaling will undoubtedly play an increasingly important role in predicting the toxicity of environmental chemicals in humans from studies in animals. It is likely that the use of scaling methodologies will also reduce the cost of evaluating the possible toxicity of a chemical to humans. A number of examples of important metabolic detoxication enzyme reactions have been listed to provide insight into the breadth of detoxication processes occurring in mammalian tissue; this list of metabolic processes is not exhaustive. We anticipate that the list of well-studied detoxication enzyme reactions will increase in the future. The data will provide a framework to use the pharmacokinetic information outlined here to give useful in vitroin vivo correlations to help us understand the mechanism of action of important chemicals of environmental concern.
